News | 05 December 2012
An FDA spokeswoman said she couldn't comment on the agency's decision-making process about the generic drugs because of a pending lawsuit by Endo seeking to block approval of the generics. But she said the agency "understands how important it is to ...
Click on the link to read the full article at Wall Street Journal
(This link will open in a new window)